1 / 10

Prof. Jean-Marc Nabholtz, MD, MSc Chairman

Prof. Jean-Marc Nabholtz, MD, MSc Chairman. Cancer Therapy Development. NEW SINGLE AGENT. Addition to Prior standard. MBC. ADJUVANT. Nabholtz, May, 2001. Evolution. BCIRG is the Breast Cancer division of CIRG (Cancer International Research Group)

selma
Download Presentation

Prof. Jean-Marc Nabholtz, MD, MSc Chairman

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prof. Jean-Marc Nabholtz, MD, MSc Chairman

  2. Cancer Therapy Development NEW SINGLE AGENT Addition to Prior standard MBC ADJUVANT Nabholtz, May, 2001

  3. Evolution • BCIRG is the Breast Cancer division of CIRG (Cancer International Research Group) • Present evaluation of potential other divisions • Disease sites eg. LCIRG, GICIRG… • Mechanistic groups: Kinase Inhibitors IRG …others?... • Integration of activities in Global Translational Processes. • with UCLA/JCCC and other Universities • Development of Translational Tools (Cancer International Tumor Bank)….

  4. Global Translational Processes

  5. Multistep Process: 7 major steps • 1. Identification of Gene abnormalities • 2. Determination of relevance in human cancers • 3. Pathway Identification • 4. Identification of therapeutic interventions • 5. Identifications of patients sub-populations with given abnormality / Tests • 6. Identification of predictive factors / Tests • 7. Pivotal clinical development

  6. Translationnal Multistep Process(7 of 7) • Pivotal Global Clinical Development • Acces to multiple targeted subpopulations in a timely fashion for proof of concept in humans CIRG First Academic Global Translational Intergroup

  7. Meeting the Challenges • Phenomenal acceleration of new compounds • Emergence of targeted therapies in subpopulations • Concept of biology based individualized therapy • Need to define new models of development and define new translational strategies • Patient Access • Overall stable number of patients • Targeted therapies: Need to study subpopulations • Need for new processes for developing new drugs

  8. Summary: Science is our guide • BCIRG and CIRGwere created to meet that need • The concept has been proven to work • Integrated Translational approach • Academic Global Translational collaboration

More Related